Hims Is Begging Customers to Lobby the FDA to Keep Its Ozempic Knockoffs Legal
Briefly

Hims, the telehealth startup known for treatments like erectile dysfunction and hair loss, is focusing on maintaining access to GLP-1 medications amidst regulatory pressures. Following a significant supply shortage in 2024, Hims saw substantial revenue growth from its weight loss product, Faux-zempic. However, renewed FDA regulations threaten its market position, leading the company to initiate a campaign encouraging users to advocate for their access to these vital treatments. This movement sees consumers submitting letters to the FDA as a measure of support to counteract regulatory challenges.
I ask you to consider the real, life-changing impact of these treatments. Please ensure that patients continue to have access to compounded GLP-1s as a critical part of health management.
Hims decided to roll out a brave new strategy to combat federal regulations: e-begging.
With all that money on the line, Hims has decided to roll out a brave new strategy to combat federal regulations: e-begging.
Hims bragged that its Faux-zempic brought in a cool $225 million in revenue in 2024, with an estimated $725 million in weight-reduction revenue on the way in 2025.
Read at Futurism
[
|
]